Lithium Carbonate NDC 0054-0886

NDC codes

FDA NDC Directory

Product NDC (as listed)0054-0886Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00054-0886Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0054-0886-25	00054088625	100 TABLET in 1 BOTTLE (0054-0886-25)Marketed from Aug 16, 2026
0054-0886-31	00054088631	1000 TABLET in 1 BOTTLE (0054-0886-31)Marketed from Aug 16, 2026

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lithium Carbonate
Generic name (nonproprietary): lithium carbonate
Active ingredients: Lithium carbonate — 300 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Hikma Pharmaceuticals USA Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 018558
Marketing start: Aug 16, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 0054-0886_e89451be-87c9-43df-b41f-b028e56e2c2fSPL ID e89451be-87c9-43df-b41f-b028e56e2c2fSPL set ID b839ff4b-f62d-41ab-a823-550a756d58ecRxCUI 197889, 197890, 197893, 311355UNII 2BMD2GNA4VUPC 0300540887254, 0300540891251, 0300540886257, 0300540890254
Pharmacologic class: Mood Stabilizer

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400054088625 followed by a unit qualifier and the quantity

Package 00054-0886-25. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 16, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder: • Treatment of acute manic and mixed episodes in patients 7 years and older [see Clinical Studies ( 14 )] • Maintenance treatment in patients 7 years and older [see Clinical Studies ( 14 )] Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder: • Treatment of acute manic and mixed episodes in patients 7 years and older ( 1 ) • Maintenance treatment in patients 7 years and older ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 018558

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 018558
Product	Strength	Form · route	Labeler	Product NDC
Lithium Carbonate	Lithium carbonate 300 mg/1	TabletOral	Hikma Pharmaceuticals USA Inc.	0054-4527
Lithium Carbonate	Lithium carbonate 300 mg/1	TabletOral	REMEDYREPACK INC.	70518-1481
Lithium Carbonate	Lithium carbonate 300 mg/1	TabletOral	Hikma Pharmaceuticals USA Inc.	0054-8528
Lithium Carbonate	Lithium carbonate 300 mg/1	TabletOral	PD-Rx Pharmaceuticals, Inc.	72789-174